Subjects enrolled in this trial will be randomly assigned to receive either Empagliflozin 10 mg or placebo for 12 weeks.
- Patients with CHF diagnosed for at least 3 months before Visit 1 and currently in NYHA class II-IV - CHF with preserved EF defined as left ventricular ejection fraction (LVEF) > 40% as per echocardiography at Visit 1 and no prior measurement of LVEF ≤ 40% - Elevated NT-proBNP > 300 pg/ml for patients without atrial fibrillation (AF), OR > 600 pg/ml for patients with AF - Patients must be on an appropriate and stable dose of oral diuretics for at least 2 weeks prior to Visit 1. - Clinically stable at randomization with no signs of heart failure decompensation
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
University of Colorado Hospital
Neda Rasouli, MD
Protocol Number: 18-0925
More information available at ClinicalTrials.gov: NCT03448406
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers